PREDICTING ANTI-LEUKEMIA ACTIVITY OF THE BCL-2-SELECTIVE INHIBITOR ABT-199 IN BCP-ALL BY FUNCTIONAL ASSESSMENT OF APOPTOSIS SIGNALING

被引：0
|
作者：
Seyfried, F. [1 ]
Demir, S. [1 ]
Hoerl, R. [1 ]
Ryan, J. [2 ]
Scheffold, A. [3 ]
Villalobos-Ortiz, M. [2 ]
Koehrer, S. [1 ]
Zinngrebe, J. [1 ]
Stilgenbauer, S. [3 ]
Letai, A. [2 ]
Debatin, K. -M. [1 ]
Meyer, L. H. [1 ]
机构：
[1] Ulm Univ, Med Ctr, Dept Pediat & Adolescent Med, Ulm, Germany
[2] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[3] Ulm Univ, Med Ctr, Dept Internal Med 3, Ulm, Germany
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P508
引用
收藏
页码：193 / 194
页数：2
相关论文
共 31 条
  • [21] Erratum: Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
    D C Phillips
    Y Xiao
    L T Lam
    E Litvinovich
    L Roberts-Rapp
    A J Souers
    J D Leverson
    Blood Cancer Journal, 2016, 6 : e403 - e403
  • [22] Correlative biomarkers of clinical activity of the BCL-2 inhibitor, venetoclax (ABT-199/GDC-0199), in acute myeloid leukemia patients
    Popovic, Relja
    Daver, Naval
    Ruvolo, Vivian
    Chen, Ken
    Wang, Zixing
    Huang, Xin
    Mabry, Mack
    Potluri, Jalaja
    McKeegan, Evelyn
    Konopleva, Marina
    Chyla, Brenda J.
    CANCER RESEARCH, 2016, 76
  • [23] BCL-2 Antagonist ABT-199 Combined with Complex I Inhibitor IACS-010759 Blocks Mitochondrial Respiration and Facilitates Anti-Leukemia Efficacy in Pre-Clinical AML Models
    Zhang, Qi
    Han, Lina
    Cai, Tianyu
    Kuruvilla, Vinitha Mary
    Cavazos, Antonio
    Ma, Helen
    Battula, Venkata Lokesh
    Baran, Natalia
    Harutyunyan, Karine
    Andreeff, Michael
    Tabe, Yoko
    Marszalek, Joseph R.
    Konopleva, Marina
    BLOOD, 2017, 130
  • [24] Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199) (vol 5, e368, 2015)
    Phillips, D. C.
    Xiao, Y.
    Lam, L. T.
    Litvinovich, E.
    Roberts-Rapp, L.
    Souers, A. J.
    Leverson, J. D.
    BLOOD CANCER JOURNAL, 2016, 6 : e403 - e403
  • [25] Selective Inhibitor of Nuclear Export Selinexor (KPT-330) and BCL2 Inhibitor ABT-199 Enhance the Anti-Lymphoma Effect of BTK Inhibitor Ibrutinib in Mantle Cell Lymphoma
    Tabe, Yoko
    Harada, Masako
    Miyamae, Yuka
    Kazuno, Saiko
    Fujimura, Tsutomu
    Ueno, Takashi
    Miida, Takashi
    Konopleva, Marina
    Andreeff, Michael
    BLOOD, 2014, 124 (21)
  • [26] Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199
    Wang, Beatrice T.
    Kothambawala, Tasnim
    Wang, Ling
    Matthew, Thomas J.
    Calhoun, Susan E.
    Saini, Avneesh K.
    Kotturi, Maya F.
    Hernandez, Genevive
    Humke, Eric W.
    Peterson, Marvin S.
    Sinclair, Angus M.
    Keyt, Bruce A.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12) : 2483 - 2494
  • [27] Inhibition of XPO1 By KPT-330 (Selinexor) Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor ABT-199 (Venetoclax) through Downregulation of Mcl-1 in Acute Myeloid Leukemia
    Luedtke, Daniel A.
    Su, Yongwei
    Edwards, Holly
    Lin, Hai
    Taub, Jeffrey W.
    Ge, Yubin
    BLOOD, 2017, 130
  • [28] Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
    Seymour, John F.
    Davids, Matthew S.
    Pagel, John M.
    Kahl, Brad S.
    Wierda, William G.
    Miller, Thomas P.
    Gerecitano, John F.
    Kipps, Thomas J.
    Anderson, Mary-Ann
    Huang, David C. S.
    Rudersdorf, Nikita K.
    Gressick, Lori A.
    Montalvo, Nicholas P.
    Yang, Panning
    Busman, Todd A.
    Dunbar, Martin
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod A.
    Roberts, Andrew W.
    BLOOD, 2013, 122 (21)
  • [29] Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101), and the novel Bcl-2 selective inhibitor, ABT-199 (GDC-0199), results in superior in vitro and in vivo anti-tumor activity in models of B-cell malignancies.
    Sampath, Deepak
    Herter, Sylvia
    Ingalla, Ellen
    Herting, Frank
    Bacac, Marina
    Nannini, Michelle
    Fairbrother, Wayne J.
    Klein, Christian
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [30] Sy-1365, a Potent and Selective CDK7 Inhibitor, Exhibits Anti-Tumor Activity in Preclinical Models of Hematologic Malignancies, and Demonstrates Interactions with the BCL-XL/BCL2 Mitochondrial Apoptosis Signaling Pathway in Leukemia
    Hodgson, Graeme
    Johannessen, Liv
    Rajagopal, Nisha
    Hu, Shanhu
    Orlando, David
    Eaton, Matthew
    McKeown, Michael
    Tyner, Jeffrey W.
    Kurtz, Stephen E.
    Sprott, Kevin
    Fritz, Christian
    Di Tomaso, Emmanuelle
    BLOOD, 2017, 130
1234